Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

H. pylori eradication should be surrogate in treatment of active/inactive duodenal ulcers -- Astra Merck.

Executive Summary

HELICOBACTER PYLORI ERADICATION IN INACTIVE ULCERS SHOULD BE "SURROGATE" for prevention of duodenal ulcer relapse, Astra Merck Director of Gastrointestinal Clinical Research Garry Neil, MD, maintained at a Jan. 28 International Business Communications meeting on H. pylori in Washington, D.C. "We would suggest that cure of H. pylori infection can and should be regarded as a surrogate marker for prevention of duodenal ulcer disease irrespective of the presence of" an active crater "at the time of diagnosis," Neil said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel